Compare FGEN & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.